Effects of cod bone gelatin on bone metabolism and bone microarchitecture in ovariectomized rats.
Several animal studies have showed that gelatin may be effective for minimizing bone loss in OVX rats with established osteopenia. To gain insight into how cod bone gelatin administration affects bone loss after ovariectomy, studies were carried out focusing on bone quality and the molecular mechanisms. Eighty-four female rats were ovariectomized, 12 sham-operated, divided into six groups of 12 each and treated one week after ovariectomy either with vehicle or cod bone gelatin (0.375, 0.75, 1.5, 3, 6 mg/kg body weight) for 90 days. Bone densitometry, microCT analysis, real-time PCR analysis and biochemical analysis were used at the end of the study. After 90 days, BMD of proximal tibia and femoral neck decreased in OVX rats, whereas the loss of BMD in those regions was prevented at 3 g/kg (P<0.05). However, the BMD of midshaft femurs showed no significant differences. BV/TV, Tb.N. and Tb.Th. in the 3 g/kg group were, respectively, 30.4% (P<0.05), 145.5% (P<0.05) and 81.5% (P<0.05) higher than in the OVX group. A significant decrease was detected in urine CTX, NTX and DPD, suggesting decreased bone resorption. Treatment with 3 g/kg and 6 g/kg cod bone gelatin attenuated the increase in serum IL-1beta, IL-6 and TNF-alpha observed in the OVX group. Real-time PCR showed significantly decreased levels of mRNA expression for RANKL at the dosage of 6 g/kg and the RANKL/OPG mRNA ratio in the 3 g/kg and 6 g/kg group significantly decreased compared to the OVX group (P<0.05). In conclusion, our data confirmed that the cod bone gelatin treatment at 3 g/kg is effective in the prevention of estrogen deficient bone loss by modulating the expression of RANKL and OPG and suppressing the release of proinflammatory cytokines.
Han
XiaoLong
X
Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.
Xu
YaJun
Y
Wang
JunBo
J
Pei
XinRong
X
Yang
RuiYue
R
Li
Ning
N
Li
Yong
Y
D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000097:blood / Q000652:urine; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000033:anatomy & histology / Q000187:drug effects* / Q000378:metabolism*; D024042:Collagen Type I / Q000097:blood / Q000652:urine; D004958:Estradiol / Q000097:blood; D005260:Female; D005269:Femur / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D005780:Gelatin / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D053583:Interleukin-1beta / Q000097:blood / Q000652:urine; D015850:Interleukin-6 / Q000097:blood / Q000652:urine; D009929:Organ Size / Q000187:drug effects; D015675:Osteocalcin / Q000097:blood; D053244:Osteoprotegerin / Q000235:genetics; D010052:Ovariectomy; D016133:Polymerase Chain Reaction; D053245:RANK Ligand / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000652:urine; D014599:Uterus / Q000187:drug effects
D000596:Amino Acids; D024042:Collagen Type I; D053583:Interleukin-1beta; D015850:Interleukin-6; D053244:Osteoprotegerin; D053245:RANK Ligand; D014409:Tumor Necrosis Factor-alpha; D015675:Osteocalcin; D004958:Estradiol; D005780:Gelatin; C036020:deoxypyridinoline; D000469:Alkaline Phosphatase